Annovis Bio Inc (ANVS) - Total Liabilities
Based on the latest financial reports, Annovis Bio Inc (ANVS) has total liabilities worth $4.23 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Annovis Bio Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how Annovis Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See ANVS working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annovis Bio Inc Competitors by Total Liabilities
The table below lists competitors of Annovis Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Transpaco Ltd
JSE:TPC
|
South Africa | ZAC547.18 Million |
|
Meta Biomed Co. Ltd
KQ:059210
|
Korea | ₩58.87 Billion |
|
Chang Ho Fibre Corp
TW:1468
|
Taiwan | NT$1.66 Billion |
|
Fire & Gas Detection Technologies Ltd
TA:FGAS
|
Israel | ILA41.79 Million |
|
CBAK ENERGY TECH. NEW
F:B6JA
|
Germany | €316.70 Million |
|
Byuksan Corp
KO:007210
|
Korea | ₩285.54 Billion |
|
ALBIS Leasing AG
XETRA:ALG
|
Germany | €196.41 Million |
|
Lion Finance Group PLC
LSE:BGEO
|
UK | GBX50.23 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Annovis Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ANVS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annovis Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annovis Bio Inc (2009–2025)
The table below shows the annual total liabilities of Annovis Bio Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.23 Million | -8.39% |
| 2024-12-31 | $4.62 Million | -74.29% |
| 2023-12-31 | $17.96 Million | +133.28% |
| 2022-12-31 | $7.70 Million | +411.02% |
| 2021-12-31 | $1.51 Million | +160.47% |
| 2020-12-31 | $578.38K | -94.03% |
| 2019-12-31 | $9.69 Million | +26.80% |
| 2018-12-31 | $7.64 Million | +4.39% |
| 2017-12-31 | $7.32 Million | +4100.16% |
| 2012-12-31 | $174.36K | -97.54% |
| 2011-12-31 | $7.09 Million | +27.64% |
| 2010-12-31 | $5.55 Million | +12106.45% |
| 2009-12-31 | $45.49K | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more